Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton for their strong cash flow, pricing power, and stable margins amid ongoing inflation. Pfizer offers a 6.66% dividend yield and growth potential as COVID impacts fade, trading at a low forward P/E. Molina is in a trough year but expected to rebound with Medicaid contract maturation, serving as an inflation hedge. Halliburton benefits from rising crude prices, returning cash to shareholders through buybacks and dividends. These stocks share defensive valuations that discount current risks, appealing to investors seeking durable earnings and inflation protection.
Pfizer reported $14.5 billion in revenue for Q1, a 5.7% increase year-over-year and $649 million above estimates. The company’s acquired products contributed $3.1 billion with 22% operational growth, aiding its strategy to manage patent expirations. ...
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU, an oral PROTAC drug for advanced breast cancer. The FDA recently approved VEPPANU for estrogen receptor-positive, ...
Pfizer is currently trading at a low forward earnings multiple of 9.1x and offers a compelling 6.7% dividend yield, making it materially undervalued. The company is facing fewer losses from patent expirations than previously expected, with management...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
